VIBATIV Drug Patent Profile
✉ Email this page to a colleague
When do Vibativ patents expire, and what generic alternatives are available?
Vibativ is a drug marketed by Cumberland Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Vibativ
Vibativ was eligible for patent challenges on September 11, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VIBATIV
International Patents: | 128 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Clinical Trials: | 13 |
Patent Applications: | 1,580 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIBATIV |
What excipients (inactive ingredients) are in VIBATIV? | VIBATIV excipients list |
DailyMed Link: | VIBATIV at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIBATIV
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Theravance Biopharma, US, Inc. | Phase 4 |
Joseph L. Kuti, PharmD | Phase 4 |
Cumberland Pharmaceuticals, Inc. | Phase 4 |
Pharmacology for VIBATIV
Drug Class | Lipoglycopeptide Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for VIBATIV
US Patents and Regulatory Information for VIBATIV
VIBATIV is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIBATIV is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIBATIV
Glycopeptide phosphonate derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TREATING BACTERIAL INFECTION
Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Hydrochloride salts of a glycopeptide phosphonate derivative
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Expired US Patents for VIBATIV
International Patents for VIBATIV
When does loss-of-exclusivity occur for VIBATIV?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 04285924
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0415853
Estimated Expiration: See Plans and Pricing
Canada
Patent: 43009
Estimated Expiration: See Plans and Pricing
Patent: 26967
Estimated Expiration: See Plans and Pricing
China
Patent: 71253
Estimated Expiration: See Plans and Pricing
Patent: 0417661
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 13773
Estimated Expiration: See Plans and Pricing
Patent: 15276
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 78201
Estimated Expiration: See Plans and Pricing
Patent: 95251
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 78201
Estimated Expiration: See Plans and Pricing
Patent: 95251
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 93516
Estimated Expiration: See Plans and Pricing
Patent: 71030
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 26769
Estimated Expiration: See Plans and Pricing
Japan
Patent: 69478
Estimated Expiration: See Plans and Pricing
Patent: 07534630
Estimated Expiration: See Plans and Pricing
Patent: 11016820
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 06004336
Estimated Expiration: See Plans and Pricing
Poland
Patent: 78201
Estimated Expiration: See Plans and Pricing
Patent: 95251
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 78201
Estimated Expiration: See Plans and Pricing
Patent: 95251
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 78201
Estimated Expiration: See Plans and Pricing
Patent: 95251
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1166250
Estimated Expiration: See Plans and Pricing
Patent: 060094082
Estimated Expiration: See Plans and Pricing
Patent: 120037025
Estimated Expiration: See Plans and Pricing
Spain
Patent: 00483
Estimated Expiration: See Plans and Pricing
Patent: 77268
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 42312
Estimated Expiration: See Plans and Pricing
Patent: 0528473
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIBATIV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2271012 | See Plans and Pricing | |
Slovenia | 1292612 | See Plans and Pricing | |
Mexico | PA02012745 | DERIVADOS DE FOSFONATOS DE GLICOPEPTIDOS. (GLYCOPEPTIDE PHOSPHONATE DERIVATIVES.) | See Plans and Pricing |
Canada | 2407994 | PROCEDE D'ALKYLATION REDUCTRICE (REDUCTIVE ALKYLATION PROCESS) | See Plans and Pricing |
Poland | 359419 | See Plans and Pricing | |
Brazil | 0110530 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIBATIV
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1292612 | C 2012 002 | Romania | See Plans and Pricing | PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902 |
1292612 | 91908 | Luxembourg | See Plans and Pricing | 91908, EXPIRES: 20260501 |
1292612 | 1190036-2 | Sweden | See Plans and Pricing | PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902 |
1292612 | CA 2011 00033 | Denmark | See Plans and Pricing | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
1292612 | 417 | Finland | See Plans and Pricing | |
1292612 | 122011100062 | Germany | See Plans and Pricing | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |